Jul 23, 2026
Eli Lilly (LLY) Stock Climbs 2% on Retatrutide Weight-Loss Drug Data
Eli Lilly (LLY) stock up 2% as retatrutide shows impressive weight-loss results. FDA filing pushed to Q1 2027. Analysts see $3.8B potential by 2030.
The post Eli Lilly (LLY) Stock Climbs 2% on Retatrutide Weight-Loss Drug Data appeared first on Blockonomi.
Source: Blockonomi →Related News
- 2 hours ago
AbCellera (ABCL) Stock Surges 6% on Menopause Treatment Phase 2 Data Reveal
- 2 hours ago
Tempus AI (TEM) Stock Soars 11% on Groundbreaking Cancer AI Study and Quarterly...
- 2 hours ago
Uber (UBER) Stock Surges on Q2 Earnings Beat: Is the Rally Sustainable?
- 4 hours ago
QuantumScape (QS) Stock Surges 16.5% This Week Despite Lack of News
- 4 hours ago
Westwater Resources (WWR) Stock Soars 88% on $25M Federal Financing Deal